Attached files
| file | filename |
|---|---|
| EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 - Cidara Therapeutics, Inc. | exhibit312-10k.htm |
| EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002 - Cidara Therapeutics, Inc. | exhibit321-10k.htm |
| EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 - Cidara Therapeutics, Inc. | exhibit311-10k.htm |
| EX-23.1 - CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM - Cidara Therapeutics, Inc. | exhibit231-10k.htm |
| EX-21.1 - LIST OF SUBSIDIARIES - Cidara Therapeutics, Inc. | exhibit211-10k.htm |
| 10-K - CIDARA THERAPEUTICS, INC. 2016 FORM 10-K - Cidara Therapeutics, Inc. | cdtx10-k2016x12x31.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Cidara Therapeutics, Inc. (the “Company”) for the period ending December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof and to which this certification is attached as an exhibit (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: March 15, 2017 | By: | /s/ Matthew Onaitis | |
Matthew Onaitis Chief Financial Officer and General Counsel | |||
(Principal Financial Officer) | |||